Navigation Links
A prognostic and predictive biomarker for nonsmall cell lung cancer
Date:6/1/2010

The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone. For patients with nonsmall cell lung cancer (NSCLC), a lung cancer that kills approximately 1 million people annually, the treatment currently available is basically the same for all patients, despite the fact that some patients may respond to treatment while others may not. New biological markers and prognostic tools are urgently needed to help doctors decide on the best course of action for each NSCLC patient. It now appears that this reality is not years away, at least for NSCLC treatment.

Currently, NSCL prognosis is made based on patient's general performance and tumor staging. Still, doctors do not know which patients with NSCLC may survive for only 10 months and which for 5 years. Now, a study published ahead of print in the journal Cancer ("CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancer", DOI 10.1002/cncr.25125) presents strong evidence that a protein called cofilin (CFL1) may help doctors in determining patient prognosis and in identifying those in need of a more aggressive treatment. The study also indicates that based on this protein, doctors may decide which drugs to use, and which to avoid, when treating NSCL patients. The possibility of doctors knowing before prescription which drugs are likely to work best for each patient represents a great advance in cancer treatment.

The group led by Dr. Fbio Klamt, a researcher at the Department of Biochemistry at the Federal University of Rio Grande do Sul, Brazil found that cofilin levels can be used to indicate which patients in the early stages of the disease have a good prognosis and which do not. When studying a large collection of NSCL cancer samples, the researchers found that the biopsies in which high levels of cofilin were found were from patients who had survived for shorter periods than those from patients with lower expression of the protein.

Besides the correlation found between cofilin and patient survival, the group also investigated whether cofilin levels could provide any clues on tumor aggressiveness. According to Dr. Klamt, "cofilin is a protein associated with cell mobility. We know that poor prognosis correlates with the ability of cells to move to generate metastasis. Thus, it seemed only reasonable that cells with lower levels of this protein would be less aggressive while higher levels would provide a more aggressive behavior." Indeed, the group tested six human cell lines of 3 major types of NSCLC and found that the types with higher levels of cofilin presented a greater potential to invade other sites in the body, which indicates a more aggressive behavior. "For patients," explains Dr. Klamt, "this finding indicates that lower levels of cofilin translate into lower chances to develop metastasis, which ultimately leads to a better prognosis."

The group also found that high levels of cofilin correlate with resistance to certain anticancer drugs, especially cisplatin and carboplatin, which have long been used for treating NSCLC. Cisplatin-based chemotherapy is the standard first-line treatment for patients at an early stage and with good performance. Nevertheless, only some will respond to this treatment. Now cofilin levels may be used to distinguish between responders and non-responders. This new finding may have great impact on survival rates, as potential non-responders may benefit from different treatment options that would not be available otherwise.


'/>"/>

Contact: Marcia Triunfol
mtriunfol@gmail.com
55-248-142-0202
Publicase Comunicao Cientfica
Source:Eurekalert

Related medicine news :

1. "IPGDx, LLC Announces The Continued Validation Of Its Patented Technology For The Assessment Of Prognosis; PrognostiCheck" Getting the New Information to Patients and Do
2. Springer publishes new journal in predictive, preventive and personalized medicine
3. The Simple and Revolutionary Power to OUTSMART YOUR GENES Out April 6th -- Predictive Medicine Pioneer Dr. Brandon Colby Releases Book
4. Existence Genetics is Pioneering the Field of Predictive Medicine - Nexus Technologies Critical in Understanding and Preventing Deadly Disease
5. Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline
6. Biomarker could help doctors tailor treatment for rheumatoid arthritis
7. TGen analysis identifies biomarkers for diabetic kidney failure
8. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
9. Personalizing cancer: Creating biomarkers from tumor DNA
10. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
11. Reliable biomarkers needed for early detection of liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... ... September 18, 2017 , ... Cosmetic Town, an online ... According to the senior editor of Cosmetic Tow, “Our forum section is an interactive, ... provide answers to other forum members thinking about having cosmetic surgery. The interaction and ...
(Date:9/18/2017)... ... September 18, 2017 , ... Aegis Therapies, a national leader ... executive team adding a Chief Financial Officer following their announcement on January 1, ... support the strategic growth strategy Aegis has defined for the next several years. ...
(Date:9/18/2017)... ... , ... In the age of digital media, limiting screen time among infants ... and a convenient way to soothe fussy children. , According to a recent study, ... sensory development toys completely. , The study, entitled “Is handheld screen time use associated ...
(Date:9/18/2017)... ... September 18, 2017 , ... While Floridians confront the aftermath ... based company, has launched an aid effort focused on the elderly population that was ... over two days and left thousands homeless and displaced. , “The elderly are often ...
(Date:9/18/2017)... ... September 18, 2017 , ... Dallas and Plano Pet Sitting ... Services . The asset-based purchase combines two of the best reviewed and highly ... Park Cities Pet Sitter, says that it was clear from the outset that acquiring ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... INDIANAPOLIS , Sept. 7, 2017  Eli ... today announced actions to streamline operations to more ... to improve its cost structure. Global workforce reductions, ... program, are expected to impact approximately 3,500 positions. ... the company expects annualized savings of approximately $500 ...
(Date:9/7/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... clinical grade cell and tissue hypothermic storage and ... Rice , President and CEO, will be presenting at two ... & Renshaw 19 th Annual Global Investment Conference on ... Pacific time). The conference is being held at the New ...
(Date:9/6/2017)... 6, 2017 Eli Lilly and Company (NYSE: ... new data for galcanezumab and lasmiditan, two investigational treatments ... Headache Society (IHC) taking place Sept. 7-10 in ... highlight new, long-term data from an open-label study evaluating ... (120 mg and 240 mg) for the prevention of ...
Breaking Medicine Technology: